CORRECTION -- Myovant Sciences, Inc.

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) announced it will host a conference call to discuss its second fiscal quarter earnings on October 26, 2022, at 5:00 p.m. ET. This follows the end of the quarter on September 30, 2022. Investors can access the live webcast on Myovant's investor relations page. The firm aims to redefine care in women's and men's health with innovative therapies, having received multiple FDA and EC approvals in recent years. Myovant is also pursuing a supplemental New Drug Application for updates on MYFEMBREE based on Phase 3 trial data.

Positive

• Myovant has executed five successful Phase 3 clinical trials.
• Three regulatory approvals received from FDA for prostate cancer and women's health treatments.
• Pending supplemental New Drug Application for MYFEMBREE with FDA.

Negative

• None.

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier today by Myovant Sciences, Inc. (NYSE: MYOV), please note that the date of the conference call was omitted from the headline. The corrected release follows:

Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on October 26, 2022

Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022.

Investors and the general public may access the live webcast here. The live webcast can also be accessed by visiting the company’s investor relations page of Myovant’s website at: https://investors.myovant.com/.

The webcast will be archived on the company website for approximately one year.

ABOUT MYOVANT SCIENCES 
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across oncology and women’s health leading to three regulatory approvals by the U.S. Food and Drug Administration (FDA) for men with advanced prostate cancer, women with heavy menstrual bleeding associated with uterine fibroids, and premenopausal women with moderate to severe pain associated with endometriosis, respectively. Myovant also has received regulatory approvals by the European Commission (EC) and the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) for women with symptomatic uterine fibroids and for men with advanced hormone-sensitive prostate cancer. Myovant has a supplemental New Drug Application under review with the FDA for updates to the United States Prescribing Information (USPI) based on safety and efficacy data from the Phase 3 LIBERTY randomized withdrawal study (RWS) of MYFEMBREE in premenopausal women with heavy menstrual bleeding due to uterine fibroids for up to two years. Myovant also is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis. In addition, Myovant is developing MVT-602, an investigational oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is Myovant’s majority shareholder. For more information, please visit www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Uneek Mehra
Chief Financial and Business Officer
Myovant Sciences, Inc.
investors@myovant.com

Media Contact:
Noelle Cloud Dugan
Vice President, Corporate Communications
Myovant Sciences, Inc.
media@myovant.com

FAQ

When is the Myovant Sciences earnings conference call?

The Myovant Sciences earnings conference call will be held on October 26, 2022, at 5:00 p.m. ET.

What is covered in the Myovant Sciences quarterly earnings call?

The earnings call will discuss corporate updates and financial results for the second fiscal quarter ended September 30, 2022.

How can I access the Myovant Sciences earnings call?

Investors can access the earnings call via a live webcast on Myovant's investor relations page.

What is the significance of Myovant's Phase 3 clinical trials?

Myovant's Phase 3 trials have led to three FDA approvals for treatments in oncology and women's health.